Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS) that is characterized by inflammation which typically results in significant impairment in most patients. Immune checkpoints act as co-stimulatory and co-inhibitory molecules and play a fundamental role in keeping the equilibrium of the immune system. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) and Programmed death-ligand 1 (PD-L1), as inhibitory immune checkpoints, participate in terminating the development of numerous autoimmune diseases, including MS. We assessed the CTLA-4 and PD-L1 gene expression in the different cell types of peripheral blood mononuclear cells of MS patients using single-cell RNA-seq data. Additionally, this study outlines how CTLA-4 and PD-L1 expression was altered in the PBMC samples of relapsing-remitting multiple sclerosis (RRMS) patients compared to the healthy group. Finally, it investigates the impact of various MS-related treatments in the CTLA-4 and PD-L1 expression to restrain autoreactive T cells and stop the development of MS autoimmunity.

Regulation of ctla-4 and pd-l1 expression in relapsing-remitting multiple sclerosis patients after treatment with fingolimod, ifnβ-1α, glatiramer acetate, and dimethyl fumarate drugs / Derakhshani, A.; Shadbad, M. A.; Asadzadeh, Z.; Safarpour, H.; Heydari, A.; Baradaran, B.; Leone, P.; Racanelli, V.. - In: JOURNAL OF PERSONALIZED MEDICINE. - ISSN 2075-4426. - 11:8(2021), pp. 72101-72111. [10.3390/jpm11080721]

Regulation of ctla-4 and pd-l1 expression in relapsing-remitting multiple sclerosis patients after treatment with fingolimod, ifnβ-1α, glatiramer acetate, and dimethyl fumarate drugs

Racanelli V.
2021-01-01

Abstract

Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS) that is characterized by inflammation which typically results in significant impairment in most patients. Immune checkpoints act as co-stimulatory and co-inhibitory molecules and play a fundamental role in keeping the equilibrium of the immune system. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) and Programmed death-ligand 1 (PD-L1), as inhibitory immune checkpoints, participate in terminating the development of numerous autoimmune diseases, including MS. We assessed the CTLA-4 and PD-L1 gene expression in the different cell types of peripheral blood mononuclear cells of MS patients using single-cell RNA-seq data. Additionally, this study outlines how CTLA-4 and PD-L1 expression was altered in the PBMC samples of relapsing-remitting multiple sclerosis (RRMS) patients compared to the healthy group. Finally, it investigates the impact of various MS-related treatments in the CTLA-4 and PD-L1 expression to restrain autoreactive T cells and stop the development of MS autoimmunity.
2021
8
Derakhshani, A.; Shadbad, M. A.; Asadzadeh, Z.; Safarpour, H.; Heydari, A.; Baradaran, B.; Leone, P.; Racanelli, V.
Regulation of ctla-4 and pd-l1 expression in relapsing-remitting multiple sclerosis patients after treatment with fingolimod, ifnβ-1α, glatiramer acetate, and dimethyl fumarate drugs / Derakhshani, A.; Shadbad, M. A.; Asadzadeh, Z.; Safarpour, H.; Heydari, A.; Baradaran, B.; Leone, P.; Racanelli, V.. - In: JOURNAL OF PERSONALIZED MEDICINE. - ISSN 2075-4426. - 11:8(2021), pp. 72101-72111. [10.3390/jpm11080721]
File in questo prodotto:
File Dimensione Formato  
2021 JPM_CTLA4-PDL1 MS.pdf

accesso aperto

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Creative commons
Dimensione 8.78 MB
Formato Adobe PDF
8.78 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/386889
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 19
social impact